A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

This study is testing a combination of three drugs — pirtobrutinib, venetoclax, and rituximab — for people newly diagnosed with Waldenström's macroglobulinemia (WM), a rare type of slow-growing blood cancer that produces abnormal antibody proteins. **You may be eligible if...** - You are 18 years or older - You have been newly diagnosed with WM or lymphoplasmacytic lymphoma confirmed by biopsy - You have not previously received treatment for this cancer - You have measurable disease and at least one symptom requiring treatment (e.g., anemia, neuropathy, thickened blood) - Your overall health status is adequate (ECOG score ≤2) and blood counts meet minimum requirements **You may NOT be eligible if...** - You have previously been treated for WM - You have transformed or aggressive lymphoma - You have active serious infections or certain other cancers - You are pregnant or breastfeeding - You have certain heart rhythm problems or severe liver disease Talk to your doctor to see if this trial is right for you.